Lung Cancer Detection by Screening - Presenting Circulating miRNAs as a Promising Next Generation Biomarker Breakthrough

  • Published : 2013.04.30


Lung cancer remains a major cause of morbidity and mortality worldwide, accounting for more deaths than any other cause. All the clinical practice guidelines recommended against routine screening for lung cancer have cited lack of robust evidence, at least until a few years back. However, the potential to screen lung cancers has received renewed interest due to superior performance of low dose CT (LD-CT) in detecting early stage cancers. The incremental costs and risks involved due to the invasive procedures in the screened population due to a high false positivity rate questions the use of LD-CT scan as a reliable community based screening tool. There is therefore an urgent need to find a less invasive and a more reliable biomarker that is crucial to increase the probability of early lung cancer detection. This can truly make a difference in lung cancer survival and at the same time be more cost and resource utilization effective. Sampling blood serum being minimally invasive, low risk and providing an easy to obtain biofluid, needs to be explored for potential biomarkers. This review discusses the use of circulatory miRNAs that have been able to discriminate lung cancer patients from disease free controls. Several studies conducted recently suggest that circulating miRNAs may have promising future applications for screening and early detection of lung cancer.


  1. Aberle DR, Adams AM, Berg CD, et al (2011). National lung screening trial research team reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med, 365, 395-409.
  2. Adriano MP, Sandro MP, Matteo Giaj-Levra, et al (2012). Clinical implications and added costs of incidental findings in an early detection study of lung cancer by using lowdose spiral computed tomography. Clinical Lung Cancer, 14, 139-48.
  3. Avila-Moreno F, Urrea F, Ortiz-Quintero B (2011). MicroRNAs in diagnosis and prognosis in lung cancer. Rev Invest Clin, 63, 516-35.
  4. Bach PB, Jett JR, Pastorino U, et al (2007). Tockman MS, Swensen SJ, Begg CB: computed tomography screening and lung cancer, JAMA, 297, 953-61.
  5. Bartel DP (2009). MicroRNAs: target recognition and regulatory functions. Cell, 136, 215-33.
  6. Bellomi M, Rampinelli C, Funicelli L, Veronesi G (2006). Screening for lung cancer. Cancer Imaging, 6, 9-12.
  7. Bianch F, Nicassio1y F, Marzi1 M, et al (2011). A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Med, 3, 495-503.
  8. Boeri M, Verri C, Conte D, et al (2011). MicroRNA signatures in tissues and cancer. Cancer Imaging, 6, 9-12.
  9. Chen X, Ba Y, Ma L, et al (2008). Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res, 18, 997-1006.
  10. Cortez MA, Calin GA (2009). MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther, 9, 703-711
  11. Crowell RE, Goetz T, Wiggins C, et al (2007). Regional disparities in treatment and survival of early stage non-small cell lung cancer. Ethn Dis, 17, 358-64.
  12. Deiderich S, Lentschig, Overbeck, et al (2001). Detection of pulomonary nodules at spiral CT: comparison of maximum intensity projection sliding slabs and single image reporting. Eur J Radiol 11, 1345-50. detected lung cancer. Proc Natl Acad Sci USA, 108, 3713-8.
  13. Foss KM, Sima C, Ugolini D, et al (2011). miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol, 6, 482-8.
  14. Heneghan HM, Miller N, Kerin MJ (2010). Circulating miRNA signatures: promising prognostic tools for cancer. J Clin Oncol, 28, 573-4.
  15. Hennessey PT, Sanford T, Choudhary A, et al (2012). Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One, 7, 32307.
  16. Henschke CI, Yankelevitz DF, Libby DM (2006). Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med, 355, 1763-71.
  17. Henschke CI, Yip R, Yankelevitz DF, Miettinen OS (2006). Computed tomography screening for lung cancer : prospects of surviving competing causes of death. Clin Lung Cancer, 7, 323-5.
  18. Hu Z, Chen X, Zhao Y (2010). Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol, 28, 1721-6.
  19. Huang Z, Huang D, Ni S, et al (2010). Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer, 127, 118-26.
  20. Iorio MV, Croce CM (2009). MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol, 27, 5848-56.
  21. Jemal A, Bray F, Melissa M, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
  22. Kaneko M, Eguchi K, Ohmatsu H, et al (1996). Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology, 201, 798-802.
  23. Keller A, Leidinger P, Gislefoss R, et al (2011). Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis. RNA biology, 8, 506-16.
  24. Kloosterman WP, Plasterk RH (2006). The diverse functions of microRNAs in animal development and disease. Dev Cell, 11, 441-50.
  25. Krishnamurthy A, Vijayalakshmi R, Gadigi V, et al (2012). The relevance of non-smoking associated lung cancer in India: A Single centre experience. Ind J Cancer, 49, 82-8.
  26. Le HB, Zhu WY, Chen DD, et al (2012). Evaluation of dynamic change of serum miR-21 and miR-24 in pre-and postoperative lung carcinoma patients. Med Oncol, 29, 3190-7.
  27. Miettinen OS (2000). Screening for lung cancer: can it be costeffective? CMAJ, 162, 1431-6.
  28. Mitchell PS, Parkin RK, Kroh EM, et al (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA, 105, 10513-8.
  29. Ou SH, Ziogas A, Zell JA (2009). Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J Thorac Oncol, 4, 37-43.
  30. Rabinowits G, Gercel-Taylor C, Day JM, et al (2009). Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer, 10, 42-6.
  31. Shen J, Todd NW, Zhang H, et al (2011) Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest, 91, 579-87.
  32. Sone S, Li F, Yang ZG, et al (2001). Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer, 84, 25-32
  33. Sone S, Takashima S, Li F, et al (1998). Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet, 351, 1242-5.
  34. Stefani G, Slack FJ (2008). Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol, 9, 219-30.
  35. Swaminathan R, Shantha V, Ferley J, et al (2011). Trends in cancer incidence in Chennai city (1982-2006) and statewide predictions of future burden in Tamilnadu (2007-16). Nat Med J India, 24, 72-7.
  36. Tsujiura M, Ichikawa D, Komatsu S, et al (2010). Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer, 102, 1174-9.
  37. Vasudevan S, Tong Y, Steitz JA (2007). Switching from repression to activation: microRNAs can up-regulate translation. Science, 318, 1931-4.
  38. Wei J, Gao W, Zhu CJ, et al (2011). Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer, 30, 407-14.
  39. Welch HG, Black WC (2010). Overdiagnosis in cancer. J Natl Cancer Inst, 102, 605-13.
  40. Welch HG, Woloshin S, Schwartz LM, et al (2007). Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. Arch Intern Med, 167, 2289-95.
  41. Wiener RS, Schwartz LM, Woloshin S, et al (2011). Populationbased risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann Intern Med, 155, 137-44.
  42. Xie Y, Todd NW, Liu Z (2010). Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer, 67, 170-6.
  43. Xu P, Guo M, Hay BA (2004). MicroRNAs and the regulation of cell death. Trends Genet, 20, 617-24.
  44. Yuxia M, Zhennan T, Wei Z (2012). Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. J Cancer Res Clin Oncol, 138, 2045-50.
  45. Zheng D, Haddadin S, Yong Wang (2011). Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol, 4, 575-86.

Cited by

  1. Clinical Observations on the Association Between Diagnosis of Lung Cancer and Serum Tumor Markers in Combination vol.14, pp.7, 2013,
  2. Advances in the Early Detection of Lung Cancer using Analysis of Volatile Organic Compounds: From Imaging to Sensors vol.15, pp.11, 2014,
  3. MicroRNAs: Biogenesis, Roles for Carcinogenesis and as Potential Biomarkers for Cancer Diagnosis and Prognosis vol.15, pp.18, 2014,
  4. Cancer: Scenario and Relationship of Different Geographical Areas of the Globe with Special Reference to North East-India vol.15, pp.8, 2014,
  5. Decreased expression and clinical significance of miR-148a in hepatocellular carcinoma tissues vol.19, pp.1, 2014,
  6. Expression of Tumor Necrosis Factor Receptor-associated Factor 6 in Lung Cancer Tissues vol.15, pp.24, 2015,
  7. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China vol.16, pp.12, 2015,
  8. Upregulation and Clinicopathological Significance of Long Non-coding NEAT1 RNA in NSCLC Tissues vol.16, pp.7, 2015,
  9. Differentially Expressed Genes in Metastatic Advanced Egyptian Bladder Cancer vol.16, pp.8, 2015,
  10. Pilot Study of Serum MicroRNA-21 as a Diagnostic and Prognostic Biomarker in Egyptian Breast Cancer Patients vol.19, pp.3, 2015,
  11. MicroRNA-141 Is a Biomarker for Progression of Squamous Cell Carcinoma and Adenocarcinoma of the Lung: Clinical Analysis of 125 Patients vol.235, pp.3, 2015,
  12. Diagnosing Lung Cancers through Examination of Micro-RNA Biomarkers in Blood, Plasma, Serum and Sputum: A Review and Summary of Current Literature vol.17, pp.4, 2016,
  13. Clinical Evaluation and Therapeutic Monitoring Value of Serum Tumor Markers in Lung Cancer vol.31, pp.1, 2016,
  14. Universal disease biomarker: can a fixed set of blood microRNAs diagnose multiple diseases? vol.7, pp.1, 2014,